Use of almotriptan in triptan-experienced and triptan-naïve patients

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2433-2440

  Pascual, Julio ^a   Diener, Hans Christoph ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Almotriptan; Efficacy; Migraine; Treatment; Triptan experienced; Triptan na ve

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; ELETRIPTAN; ERGOTAMINE DERIVATIVE; NARATRIPTAN; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; ZOLMITRIPTAN;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HUMAN; META ANALYSIS; MIGRAINE; NAUSEA; PHONOPHOBIA; PHOTOPHOBIA; POST HOC ANALYSIS; QUESTIONNAIRE; REVIEW; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING;

HUMANS; MIGRAINE DISORDERS; PATIENT SATISFACTION; PLACEBOS; SEROTONIN AGONISTS; TRYPTAMINES;

EID: 35648942764     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X232990     Document Type: Review

References (24)

1. World Health Organization. The global burden of disease. Geneva: WHO, 2003
2. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache 1999;39(Suppl 2):S20-6
3. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60:1259-87
4. Diener HC, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Investig Drugs 2001;10:1831-45
5. 1B/1D receptor agonists. Arch Neurol 2002;59:1084-8
6. Diener HC. Pharmacological approaches to migraine. J Neural Transm Suppl 2003;64:35-63
7. Silberstein SD. Migraine. Lancet 2004;363:381-91
8. Saper JR. What matters is not the differences between triptans, but the differences between patients. Arch Neurol 2001;58:1481-3
9. Stark S, Spierings ELH, McNeal S, et al. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000;40:513-20
10. Färkkilä M, Olesen J, Dahlöf CGH, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463-71
11. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Headache 2005;45:874-82
12. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005;45:156-62
13. Dahlöf CGH. Infrequent or non-response to oral sumatriptan does not predict response to other triptans - review of four trials. Cephalalgia 2006;26:98-106
14. Rapoport AM, Tepper SJ. Triptans are all different. Arch Neurol 2001;58:1479-80
15. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
16. Dahlöf C, Tfelt-Hansen P, Massiou H, et al. Dose finding, placebo-controlled study of oral almotriptan in the treatment of acute migraine. Neurology 2001;57:1811-17
17. Dahlöf C, Pascual J, Dodick DW, et al. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26:400-8
18. Dodick, DW. A review of the clinical efficacy and tolerability of almotriptan in acute migraine. Expert Opin Pharmacother 2003;4:1157-63
19. Iglesias-Diez F, Straube A, Zanchin G. Patient preference in migraine therapy: a randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol 2007;254:242-9
20. Diener HC. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients with previous poor response to sumatriptan 50 mg. Curr Med Res Opin 2005;21:1603-10
21. Massiou H, Pradalier A, Donnet A, et al. Evaluation of efficacy, tolerability, and treatment satisfaction with almotriptan in 3 consecutive migraine attacks. Eur Neurol 2006;55:198-203
22. Geraud G, Lanteri-Minet M, Lucas C, et al. French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004;26:1305-18
23. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007;115:34-40
24. Diener HC. Consistent efficacy, tolerability and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice. Headache 2005;45:624-31